Theresa Heggie

Track

Insider profile

Currently holds a position at BioCryst Pharmaceuticals Inc

Performance

Overall performance
3.5
Performance over holding periods
3.5
30 days 90 days 120 days
Average return 7% 8.2% 15.1%
Success rate 96% 68% 82%
Transactions
3 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Director BioCryst Pharmaceuticals Inc Dec. 3, 2018 -
Senior Vice President, Head of Europe and Canada Alnylam Pharmaceuticals Inc May 9, 2017 - Jan. 1, 2018
Independent Director Swedish Orphan Biovitrum AB (publ) May 24, 2016 - April 7, 2017
Theresa Heggie's trades of BioCryst Pharmaceuticals Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Proposed sale
Price
112.66
Quantity 99,099
Value US$4,266,364
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-03-24 2026-03-20
S Sale
7,063 -17.4%
487.84
US$4,909,409 		7,063 -17.4% 487.84 US$4,909,409
2026-03-20 2026-03-20
PrS Proposed sale
99,099
112.66
US$4,266,364 		99,099 112.66 US$4,266,364
2025-08-15 2025-08-13
S Sale
57,206 -33.5%
377.60
US$3,510,203 		57,206 -33.5% 377.60 US$3,510,203
2025-08-13 2025-08-13
PrS Proposed sale
70,000
8.51
US$595,871 		70,000 8.51 US$595,871
2024-06-14 2024-06-14
PrS Proposed sale
6,698
6.08
US$40,746 		6,698 6.08 US$40,746
2024-06-14 2024-06-14
S Sale
6,698 -11.2%
6.11
US$40,925 		6,698 -11.2% 6.11 US$40,925